JAK/STAT Signaling(JAK/STAT 信号通路)

Products for JAK/STAT Signaling
- Cat.No. 产品名称 Information
-
GC25992
TG-89
TG-89 is an inhibitor of JAK2 with IC50 of 11.2 μM.
-
GC25899
SC-1
SC-1 (1-(4-Chloro-3-(trifluoromethyl)phenyl)-3-(4-(4-cyanophenoxy)phenyl)urea, STAT3-IN-7), a Sorafenib analogue and potently inhibits the phosphorylation of STAT3, induces cell apoptosis through SHP-1 dependent STAT3 inactivation.
-
GC25869
RO495
RO495 (CS-2667) is a potent inhibitor of Non-receptor tyrosine-protein kinase 2 (TYK2).
-
GC25559
Lapatinib (GW-572016) Ditosylate
Lapatinib (GW-572016) Ditosylate is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively.
-
GC25219
CH7233163
CH7233163 is a non-covalent ATP competitive inhibitor of EGFR-tyrosine kinase with antitumor activities against tumor with EGFR-Del19/T790M/C797S.
-
GC25168
Brepocitinib (PF-06700841)
Brepocitinib (PF-06700841, PF-841) is a potent inhibitor of Tyk2 and Jak1 with IC50s of 23 nM, 17 nM, 77 nM for Tyk2, Jak1 and Jak2 respectively. It has appropriate in-family selectivity against JAK2 and JAK3.
-
GC67958
HP590
-
GC67867
VVD-118313
-
GC67860
JBJ-09-063 TFA
-
GC67779
STX-0119
-
GC67759
Lapatinib-d4
-
GC67749
Amivantamab
-
GC67706
LY5
-
GC67690
JBJ-09-063 hydrochloride
-
GC52293
STAT3 Inhibitor 4m
A STAT3 inhibitor
-
GC66432
EAI001
-
GC66428
EGFR-IN-5
-
GC66405
Panitumumab
Panitumumab (anti-EGFR, ABX-EGF) is a recombinant, fully human IgG2 monoclonal antibody that binds to the epidermal growth factor receptor (EGFR).
-
GC66333
Panitumumab (anti-EGFR)
-
GC66329
NDI-034858
-
GC65992
FGFR2-IN-3
-
GC65991
FGFR2-IN-3 hydrochloride
-
GC65974
EGFR-IN-9
-
GC65572
EGFR Protein Tyrosine Kinase Substrate
-
GC65453
JAK-IN-3
-
GC65436
JND3229
JND3229 is a potent reversible inhibitor of EGFRC797S with an IC50 value of 5.8 nM. JND3229 also potently suppresses EGFRL858R/T790M and EGFRWT with IC50 values of 30.5 nM and 6.8 nM, respectively.
-
GC65405
JAK2-IN-6
-
GC65387
Tyk2-IN-5
-
GC65344
STAT5-IN-2
STAT5-IN-2 inhibits the growth of acute and chronic myeloid leukemia cells and the phosphorylation and transcriptional activity of STAT5, but not STAT3, AKT, or Erk1/2 phosphorylation, with minimal effects on bone marrow stromal cells that play vital functions in the microenvironment of hematopoietic and leukemic cells.
-
GC65310
TAS0728
A covalent HER2 inhibitor
-
GC65278
PIM1-IN-1
-
GC65201
Quercetagetin
A selective Pim-1 inhibitor
-
GC65020
Danvatirsen
-
GC64959
JAK/HDAC-IN-1
-
GC64891
YM-341619
-
GC64774
SEL24-B489
-
GC64770
Oritinib
-
GC64710
MC-Val-Cit-PAB-Amide-TLR7 agonist 4
-
GC64701
Povorcitinib
-
GC64700
Povorcitinib phosphate
-
GC64497
EGFR-IN-17
-
GC64398
Almonertinib mesylate
-
GC64372
Lorpucitinib
-
GC64302
BAY 2476568
-
GC64108
Ifidancitinib
-
GC64039
Disitamab vedotin
-
GC64017
Befotertinib
-
GC63910
BLU-945
BLU-945 is a potent, highly selective, reversible and orally active epidermal growth factor receptor(EGFR) tyrosine kinase inhibitor (TKIs). BLU-945 can be used for the research of lung cancer including non-small cell lung cancer (NSCLC).
-
GC63864
(E/Z)-Zotiraciclib hydrochloride
-
GC63797
(S)-Sunvozertinib
DZD9008 (Sunvozertinib) is an oral, potent, irreversible, wild type-selective EGFR inhibitor against EGFR or HER2 Exon20ins and other mutations with IC50 ranging from 0.4 nM to 2.1 nM for mutant EGFR.